Business
Jazz Pharmaceuticals Announces First Patient Enrolled in IMforte Phase 3 Trial Evaluating Zepzelca® (lurbinectedin) in Combination with a PD-L1 Inhibitor in Small Cell Lung Cancer
Registrational trial will assess the potential for a novel combination therapy in extensive-stage small cell lung cancer to deliver better long-term outcomes
About this update from Jazz Pharmaceuticals Plc
[{"type":"text","content":"Registrational trial will assess the potential for a novel combination therapy in extensive-stage small cell lung cancer to deliver better long-term outcomes\n\n\nDUBLIN, Nov. 30, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient was enrolled in a Phase 3 clinical trial evaluating Zepzelca® (lurbinectedin) in combination with the PD-L1 inhibitor Tecentriq® (atezolizumab) as a first-line maintenance treatment for patients with extensive-stage small cell lung cancer (ES-SCLC). The trial, IMforte, conducted in collaboration with F. Hoffmann-La Roche Ltd, will measure the progression-free survival and overall survival benefits of Zepzelca and Tecentriq administered in combination compared to Tecentriq alone. \n\"Small cell lung cancer can progress faster than most forms of lung cancer, although new treatment options can prolong life and improve long-term care options,\" said Luis Paz-Ares, M.D., Ph.D., professor of medicine at Hospital Universitario 12 de Octubre in Madrid, Spain. \"Jazz's collaborative research with Roche will provide much-needed insights into a potentially new small cell lung cancer therapeutic option in the first-line setting. With approximately a quarter million patients diagnosed globally with small cell lung cancer each year – including thousands in the U.S. alone – a new first-line maintenance combination treatment would be a welcome advancement for patients with extensive disease.\" \n\"We've already witnessed strong clinical demand for Zepzelca as a therapy for metastatic small cell lung cancer patients in the second-line setting,\" said Rob Iannone, M.D., M.S.C.E., executive vice president, research and development and chief medical officer at Jazz Pharmaceuticals. \"This collaboration with Roche marks an opportunity to further study Zepzelca's safety and efficacy in combination with the PD-L1 inhibitor, Tecentriq, in a pivotal Phase 3 clinical trial, as part of a first-line, standard-of-care, immunotherapy treatment option for patients with extensive-stage small cell lung cancer, a devastating disease for which novel treatments and strategies are needed.\"\nAbout the IMforte Phase 3 TrialAs part of the IMforte Phase 3, randomized, multicenter maintenance trial, Jazz and Roche will evaluate the efficacy, safety and pharmacokinetics of Zepzelca plus Tecentri...